Mirna Therapeutics, which is developing microRNA replacement therapies for liver cancer, raised $44 million by offering 6.3 million shares at $7. Mirna Therapeutics plans to list on the Nasdaq under the symbol MIRN. Mirna Therapeutics initially filed confidentially on 3/12/2014. Citi and Leerink Partners acted as lead managers on the deal.
